New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:25 EDTTSPT, PFE, NKE, WAG, HALO, RHT, RIMM, CEMIOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Red Hat (RHT), up 5.4%... Nike (NKE), up 3%... ALSO HIGHER: Chembio Diagnostics (CEMI), up 20.7% after receiving FDA approval for its rapid HIV test... Halozyme (HALO), up 17.4% after entering a development collaboration with Pfizer (PFE)... Ameristar Casinos (ASCA), up 17% after agreeing to be acquired by Pinnacle Entertainment (PNK) for $26.50 per share... LOWER AFTER EARNINGS: Research in Motion (RIMM), down 16.3%... Walgreen (WAG), down 1.7%... ALSO LOWER: Transcept (TSPT), down 14.7% after Phase 2 trial of OCD drug misses primary endpoint.
News For RHT;NKE;CEMI;HALO;PFE;RIMM;WAG;TSPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
12:06 EDTPFEPfizer receives orphan status for lung cancer drug
The FDA granted Pfizer orphan status for its treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations, dacomitinib.
08:37 EDTPFEPfizer says EC approves expanded indication for Prevenar 13
Pfizer announced that the European Commission approved an expanded indication for the use of Prevenar 13 -- pneumococcal polysaccharide conjugate vaccine 13-valent, adsorbed -- for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. The Summary of Product Characteristics has also been updated to include efficacy data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults, which demonstrated statistically significant reductions in first episodes of vaccine-type pneumococcal community-acquired pneumonia, including non-invasive/non-bacteremic CAP, and invasive pneumococcal disease in adults aged 65 and older.
March 2, 2015
16:41 EDTHALOHalozyme sees 2015 revenue $85M-$95M, consensus $97.69M
Subscribe for More Information
16:41 EDTHALOHalozyme reports Q4 EPS (4c), consensus (7c)
Reports Q4 revenue $30.4M, consensus $25.59M.
16:31 EDTPFEPfizer files automatic mixed securities shelf
Subscribe for More Information
09:02 EDTPFEAstraZeneca mulls linking bonuses to Pfizer defense pledges, Sunday Times says
Subscribe for More Information
February 26, 2015
12:31 EDTPFEPfizer says CDC recommends serogroup B meningococcal vaccine for those at risk
Subscribe for More Information
08:50 EDTNKEKohl's says Nike sales up 24% at Kohl's stores in Q4
Kohl's (KSS) says number of transactions increased 2% in Q4. Says Nike (NKE) delivered 24% increase in Q4 sales. Expects about 900 stores to have new beauty format by end of year. Sees some margin pressure in Q1 from rollout of beauty products. Expects SG&A to increase more in Q1 than in the balance of the year. Says FY CapEx guidance includes $350M of IT spending, $250M for store strategies, $200M for base capital projects. Comments made on the Q4 earnings conference call.
February 24, 2015
08:07 EDTPFEPfizer announces Trumenba studies met primary objectives
Subscribe for More Information
February 20, 2015
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
09:23 EDTNKEGoldman sees select Apparel and Footwear opportunities due to FX risk
Goldman said translation currency exposure in the Apparel and Footwear has created volatility and opportunity to gain exposure to this theme. Goldman's analyst sees a positive near-term set-up for Nike (NKE) and Tiffany (TIF) and a negative set-up for Crocs (CROX) and Abercrombie & Fitch (ANF) and of upcoming earnings reports.
07:23 EDTPFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 19, 2015
18:25 EDTPFEPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information
February 18, 2015
10:42 EDTNKEApparel makers beyond Perry Ellis seen hurt by port slowdown
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use